Eisai publishes additional detailed analyses from lecanemab

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today the publication of additional detailed analyses from the phase...

Related Keywords

Stockholm , Sweden , Japan , China , Uppsala , Uppsala Lan , Swedish , Oskar Bosson , Vp Communications , Ministry Of Health , National Medical Products Administration , Devices Agency , National Institute On , European Medicines Agency , Drug Administration , Alzheimer Research Therapy , Alzheimer Network Trials Unit , Washington University School Of Medicine , National Institutes Of Health , Alzheimer Clinical Trial Consortium , Alzheimer Research , Uppsala University , Translational Research , Nasdaq Stockholm , Clinical Dementia Rating Sum Of Boxes , Scale Cognitive Subscale , Positron Emission Tomography , Brand Name , Clinical Trials , New England Journal , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Medical Devices Agency , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Bioarctic ,